This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative


Ellis, Kathryn A., Rowe, Christopher C., Villemagne, Victor L., Martins, Ralph N., Masters, Colin L., Salvado, Olivier, Szoeke, Cassandra, Ames, David


Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Volume: 6, No.: 3, Pages.: 291-296

Year of Publication



The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer’s disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and identify diet and lifestyle factors that influence the development of AD. For AIBL, the magnetic resonance imaging parameters of Alzheimer’s Disease Neuroimaging Initiative (ADNI) were adopted and the Pittsuburgh compound B (¹¹C-PiB) positron emission tomography (PET) acquisition and neuropsychological tests were designed to permit comparison and pooling with ADNI data. Differences to ADNI include assessment every 18-months, imaging in 25% (magnetic resonance imaging, ¹¹C-PiB PET but no fluorodeoxyglucose PET), more comprehensive neuropsychological testing, and detailed collection of diet and lifestyle data. AIBL has completed the first 18-month follow-up and is making imaging and clinical data available through the ADNI website. Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle. (PsycINFO Database Record (c) 2015 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Ellis_2010, doi = {10.1016/j.jalz.2010.03.009}, url = {}, year = 2010, month = {may}, publisher = {Elsevier {BV}}, volume = {6}, number = {3}, pages = {291--296}, author = {Kathryn A. Ellis and Christopher C. Rowe and Victor L. Villemagne and Ralph N. Martins and Colin L. Masters and Olivier Salvado and Cassandra Szoeke and David Ames}, title = {Addressing population aging and Alzheimer{textquotesingle}s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer{textquotesingle}s Disease Neuroimaging Initiative}, journal = {Alzheimer{textquotesingle}s {&} Dementia} }


aging, alzheimer’s disease, alzheimers disease neuroimaging initiative, australian imaging biomarkers and lifestyle study, biological markers, cognitive impairment, lifestyle, mild cognitive impairment, neuroimaging, population

Countries of Study


Types of Dementia

Dementia (general / unspecified), Mild Cognitive Impairment (MCI)

Types of Study

Cohort Study

Type of Outcomes


Type of Interventions

Risk Factor Modification

Risk Factor Modifications

General population health promotion